The man who claims to be the founding father of messenger RNA (mRNA) technology is making waves in the world of artificial intelligence. The start-up and the biotechnology giant Moderna came together at the beginning of 2023 around an ambitious plan consisting of integrating generative AI within it. The first step in this plan was the launch within Moderna of its own ChatGPT instance, called mChat.
Built internally on the API offered by OpenAI, the instance has been very successful. Moderna's objective was to achieve 100% adoption and mastery of generative AI by all its employees with access to digital solutions within six months. The firm, which reveals an internal adoption rate rising to more than 80% since its beginnings, can therefore be proud of itself.
Advertisement
More recently, Moderna decided to strengthen its ties with OpenAI and made the decision to deploy ChatGPT Enterprise in its different branches – commercial, legal, research, manufacturing – giving rise to the creation of several GPTs.
More than 750 “GTP” assistants deployed in all branches of the company
In detail, Moderna indicates that it has deployed more than 750 GPTs throughout the company in the space of two months. Similarly, 40% of weekly active users have created GPTs while each user has an average of 120 ChatGPT Enterprise conversations per week.
These different assistants, now integrated into Moderna's various services, are proving to be important allies for its employees. “Just as the introduction of the personal computer in the 1980s changed the way we work and live, AI is poised to completely transform our daily lives – and OpenAI is helping to lead the way,” says Stéphane Bancel, CEO of Moderna.
Advertisement
Dose ID, a GPT that evaluates the optimal vaccine dose
One, called Dose ID, uses ChatGPT Enterprise's Advanced Data Analytics feature to further evaluate the optimal vaccine dose selected by the clinical study team. “By applying standard dose selection criteria and principles, Dose ID provides rationale, references its sources, and generates informative graphics illustrating key findings,” details Moderna.
“Dose ID provided a strong rationale for why we chose a specific dose over other doses. This allowed us to create personalized data visualizations and also helped study team members converse with GPT to further analyze data from several different angles”, explains Meklit Workneh, director of clinical development at Moderna. Result: teams of researchers are now able to present a detailed examination, combining human expertise and artificial intelligence. This vaccine dosage work is also crucial before further development in late-stage clinical trials.
Other use cases, from legal to commercial
At the same time, other teams that have adopted ChatGPT demonstrate their uses. Moderna's legal team thus claims 100% adoption of the tool. “This allows us to focus our time and attention on issues that truly impact patients,” said Shannon Klinger, Moderna’s chief legal officer. A GPT specific to the legal sector has been created – Contract Companion – helping teams obtain a clear and readable summary of a contract. Another called Policy Bot helps employees get quick answers on internal policies without having to wade through hundreds of documents.
For Moderna's enterprise brand teams, there are many ways to leverage ChatGPT. They have a GPT that helps prepare slides for quarterly earnings announcements, and another GPT that helps convert biotech terminology into accessible language for investor communications.
Moderna continues its product development objective at a breakneck pace
The firm is also counting on OpenAI to carry out its strategy and launch several products over the coming years. Moderna is using its mRNA drug development platform to commercialize up to 15 products over the next 5 years, from a respiratory syncytial virus (RSV) vaccine to individualized cancer treatments.
“If we were to do it the old biopharmaceutical ways, we would need a hundred thousand people today,” explains Stéphane Bancel. And to conclude: “We truly believe we can maximize our impact on the patients of a few thousand people, using technology and AI to scale the business.”
Do you want to stay up to date on the latest news in the artificial intelligence sector? Register for free to the IA Insider newsletter.
Selected for you
